Pharmaceuticals refer to compounds manufactured for use as a medicinal drug. Companies active in the pharmaceutical industry are involved in development, production and marketing of pharmaceuticals.
The global market for pharmaceuticals is demonstrating a substantial growth in Latin America and Asia, but is relatively stable in Europe. The worldwide market is assessed at about USD 300 billion yearly. The USA, Japan, Germany, France and China are the top pharmaceutical markets. The pharmaceutical industry benefits from the ageing population; new medical discoveries and new drugs approvals; the increased number of chronic, degenerative and heart diseases, and cancer.
The research reports of this Catalogue cover all the major categories within global, regional and local pharmaceuticals markets. The reports offer overviews of the market trends, drivers; factors contributing to market growth. The challenges faced by industry participants, analyses of the top companies involved in the marketplace, and the key market news are provided in the reports.
Publications found:
26,272
Sort by:
Adalimumab-Biosimilars Insight, 2022
US$ 2,000.00
This report can be delivered to the clients within 72-96 hours DelveInsight’s, “Adalimumab– Biosimilar 2022,” report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline...
January 2022
90 pages
Bevacizumab-Biosimilars Insight, 2022
US$ 2,000.00
This report can be delivered to the clients within 96-120 hours DelveInsight’s, “Bevacizumab– Biosimilar 2022,” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeli...
January 2022
125 pages
Filgrastim - Biosimilar Insight, 2022
US$ 2,000.00
This report can be delivered to the clients within 48-72 hours DelveInsight’s, “Filgrastim– Biosimilar 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline...
January 2022
70 pages
Infliximab-Biosimilars Insight, 2022
US$ 2,000.00
This report can be delivered to the clients within 72-96 hours DelveInsight’s, “Infliximab– Biosimilar 2022,” report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline...
January 2022
90 pages
Insulin Glargine- - Biosimilar Insight, 2022
US$ 2,000.00
This report can be delivered to the clients within 72-96 hours DelveInsight’s, “Insulin Glargine– Biosimilar 2022,” report provides comprehensive insights about 10+ companies and 10+ marketed and pi...
January 2022
90 pages
Interferon - Biosimilar Insight, 2022
US$ 1,000.00
This report can be delivered to the clients within 48-72 hours DelveInsight’s, “Interferon– Biosimilar 2022,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline...
January 2022
70 pages
Ranibizumab-Biosimilars Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 72-96 hours DelveInsight’s, “Ranibizumab– Biosimilar 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipelin...
January 2022
90 pages
Rituximab-Biosimilars Insight, 2022
US$ 2,500.00
This report can be delivered to the clients within 96-120 hours DelveInsight’s, “Rituximab– Biosimilar 2022,” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline...
January 2022
125 pages
Somatotropin - Biosimilar Insight, 2022
US$ 1,000.00
This report can be delivered to the clients within 48-72 hours DelveInsight’s, “Somatropin– Biosimilar 2022,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline...
January 2022
70 pages
Trastuzumab-Biosimilars Insight, 2022
US$ 2,500.00
This report can be delivered to the clients within 96-120 hours DelveInsight’s, “Trastuzumab– Biosimilar 2022,” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeli...
January 2022
125 pages
Biliary Atresia (BA) - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Biliary Atresia (BA) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, h...
January 2022
60 pages
Follicular Lymphoma - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Follicular Lymphoma - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, hi...
January 2022
60 pages
Hypofibrinogenemia - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Hypofibrinogenemia - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, his...
January 2022
60 pages
West Syndrome - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'West Syndrome - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historic...
January 2022
60 pages
Cyclin-dependent-kinase-inhibitors - Pipeline Insight, 2022
US$ 2,500.00
This report can be delivered to the clients within 3-4 working days DelveInsight’s, “Cyclin-dependent-kinase-inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 40+ com...
January 2022
150 pages
VAP-1 Inhibitors - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “VAP-1 Inhibitors- Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline dru...
January 2022
60 pages
Anti-CD22 Therapies - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “Anti-CD22 Therapies - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline...
January 2022
60 pages
Anti-CD30 Therapies - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “Anti-CD30 Therapies - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline...
January 2022
60 pages
AXL Kinase Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “AXL Kinase Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipelin...
January 2022
60 pages
LRRK2 Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor - Pipeline Insight, 2021,” report provides comprehensive insights about 8+...
January 2022
60 pages
TGFb inhibitors - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 24 Hours DelveInsight’s, “TGF-Beta Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline...
January 2022
60 pages
TIM-3 Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “TIM-3 Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline dru...
January 2022
60 pages
Dopamine D2 receptor antagonist - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “Dopamine D2 receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and...
January 2022
60 pages
